Categories: News

Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit

SAN FRANCISCO and WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that members of management, will participate in a fireside chat at the Stifel 2024 Immunology and Inflammation Summit on Wednesday, September 18, 2024 at 12:30 p.m. E.T. / 9:30 a.m. P.T.

A live and archived webcast of the fireside chat and presentation will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.

About Apogee

Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. APG777, the company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets. With four validated targets in its portfolio, Apogee is seeking to achieve best in class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit www.apogeetherapeutics.com.

Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
noel.kurdi@apogeetherapeutics.com

Media Contact:
Dan Budwick
1AB
dan@1abmedia.com

Staff

Recent Posts

HandicapMD Expands Leading Telemedicine Services for Disabled Parking Permits in Florida

HandicapMD's virtual telemedicine platform connects patients with licensed doctors to obtain disabled parking placards quickly,…

1 hour ago

NewSound’s Commitment to Medical Device Excellence: MDD, MDR, and Beyond

XIAMEN, China, Sept. 20, 2024 /PRNewswire/ -- Founded in 2004, the whole family of NewSound…

1 hour ago

ISI Technology Makes Inc. 5000 List for the Second Consecutive Year

BUFFALO, N.Y., Sept. 20, 2024 /PRNewswire/ -- ISI Technology, a leading provider of software solutions…

1 hour ago

Stryker completes acquisition of NICO Corporation, expanding minimally invasive solutions for brain tumor removal and stroke care

PORTAGE, Mich., USA, Sept. 20, 2024 /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical…

1 hour ago

XpertDox Partners with Blue Fish Pediatrics to Enhance Medical Coding Efficiency with AI-Powered Healthcare Coding Software

XpertDox and Blue Fish Pediatrics Join Forces to Streamline Medical Coding, Enhance Clinical Documentation, and…

1 hour ago

This Week in Health News: 11 Stories You Need to See

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including…

1 hour ago